Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

HealthLynked (HLYK) EBITDA (2016 - 2025)

HealthLynked (HLYK) has disclosed EBITDA for 10 consecutive years, with -$716499.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 56.41% to -$716499.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.0 million, a 39.15% increase, with the full-year FY2024 number at -$4.6 million, down 13.28% from a year prior.
  • EBITDA was -$716499.0 for Q3 2025 at HealthLynked, down from -$655542.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.3 million in Q4 2021 to a low of -$4.1 million in Q4 2022.
  • A 5-year average of -$1.1 million and a median of -$1.1 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 414.21% in 2022, then soared 73.77% in 2023.
  • HealthLynked's EBITDA stood at $1.3 million in 2021, then crashed by 414.21% to -$4.1 million in 2022, then skyrocketed by 73.77% to -$1.1 million in 2023, then surged by 33.36% to -$720338.0 in 2024, then grew by 0.53% to -$716499.0 in 2025.
  • Per Business Quant, the three most recent readings for HLYK's EBITDA are -$716499.0 (Q3 2025), -$655542.0 (Q2 2025), and -$903341.0 (Q1 2025).